Ligand Pharmaceuticals director John W. Kozarich sold 467 shares of common stock in a planned transaction. The sales occurred on February 2, 2026 at prices ranging from $191.00 to $197.195 per share in several small trades.
After these sales, Kozarich directly beneficially owned 43,187 shares of Ligand common stock. The filing notes that the transactions were executed under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1, which allows pre-arranged trading by insiders.
Ligand Pharmaceuticals director John W. Kozarich sold 467 shares of common stock in a planned transaction. The sales occurred on February 2, 2026 at prices ranging from $191.00 to $197.195 per share in several small trades.
After these sales, Kozarich directly beneficially owned 43,187 shares of Ligand common stock. The filing notes that the transactions were executed under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1, which allows pre-arranged trading by insiders.
Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06. The shares are listed on Nasdaq, and 19,681,720 shares were outstanding at the time referenced.
The shares to be sold are common stock acquired on 04/24/2024 from the issuer in various transactions, totaling 467 shares. The filing also notes that John Kozarich has sold 467 common shares in each of three transactions over the past three months, with gross proceeds of 91,456.91, 89,219.00, and 88,532.51.
Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06. The shares are listed on Nasdaq, and 19,681,720 shares were outstanding at the time referenced.
The shares to be sold are common stock acquired on 04/24/2024 from the issuer in various transactions, totaling 467 shares. The filing also notes that John Kozarich has sold 467 common shares in each of three transactions over the past three months, with gross proceeds of 91,456.91, 89,219.00, and 88,532.51.